20/20 Biolabs, Inc. (AIDX) - 10-K Summary
Business Context and Reporting Period
Company: 20/20 Biolabs, Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: The Company develops and commercializes AI-powered, laboratory-based blood tests for early cancer detection (OneTest for Cancer) and chronic disease prevention (OneTest for Longevity). It operates a CLIA-certified, CAP-accredited laboratory in Gaithersburg, MD, and maintains a legacy business in bioterrorism screening (BioCheck). The Company is an Emerging Growth Company and Smaller Reporting Company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $2,045,133 | $1,752,343 |
| Gross Profit | $604,541 | $360,311 |
| Gross Margin | 29.56% | 20.56% |
| Operating Loss | $(3,330,871) | $(5,677,413) |
| Net Loss | $(3,738,821) | $(5,551,667) |
| Cash and Equivalents (Year End) | $1,025,987 | $1,784,009 |
| Net Cash Used in Operating Activities | $(1,919,720) | $(2,598,785) |
Revenue Breakdown (2025): OneTest for Cancer (88.2%), BioCheck (7.4%), CLIAx (4.4%).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16.7% to $2.05 million, driven by a 21.0% increase in OneTest sales (volume and mix shift to higher-priced Premium tests) and a 6.2% increase in CLIAx revenue.
- Expense Reduction: Operating expenses decreased significantly by 34.8% to $3.94 million. Sales, General, and Administrative (SG&A) expenses dropped 29.8% due to in-house marketing shifts and reduced agency spend. Research and Development (R&D) expenses fell 53.0% as major validation studies (NCI and capillary blood) were completed in 2024.
- Improved Margins: Gross margin expanded from 20.6% to 29.6% primarily due to a favorable product mix shift toward higher-margin tests.
- Reduced Net Loss: Net loss narrowed by 32.7% to $3.74 million, reflecting the reduction in operating expenses despite a $280,764 loss on the issuance of convertible notes.
Guidance, Outlook, and Risks
Recent Developments & Outlook:
- Direct Listing: Common stock began trading on Nasdaq (Symbol: AIDX) on February 19, 2026.
- Capital Raising: Subsequent to year-end, the Company raised $5.0 million via a private placement of Series E Convertible Preferred Stock and $275,000 in bridge financing.
- Product Launch: OneTest for Longevity was launched in February 2026, targeting chronic inflammation and workplace wellness.
- Regulatory Environment: The Company anticipates pursuing Medicare coverage for its MCED test, with a pathway established by the Medicare MCED Screening Coverage Act signed in February 2026.
Risks and Contingencies:
- Going Concern: The Company has incurred losses since inception and requires continued external financing to meet obligations. Management believes additional financing is obtainable but cannot guarantee terms or success.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting related to insufficient trained professionals for risk assessment and complex transaction accounting. A restatement of 2024 financial statements was required due to stock-based compensation errors.
- Regulatory: While currently operating as Laboratory Developed Tests (LDTs) under CLIA, future FDA regulation of LDTs remains a potential risk, though a recent court ruling vacated the FDA's 2024 final rule.
- Competition: Significant competition exists from ctDNA-based tests (e.g., Grail's Galleri), which are more expensive but widely marketed.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.03 million cash balance plus the $5.275 million raised in early 2026 to fund operations until profitability or further financing.
- Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting to prevent future restatements.
- Revenue Sustainability: Assess the durability of revenue growth given the heavy reliance on self-pay models and the timeline for potential Medicare reimbursement (expected 2028).
- Debt Obligations: Review terms of convertible notes and Series E Preferred Stock, including conversion triggers, interest rates, and potential dilution upon conversion.
- Product Validation: Evaluate the clinical data supporting the "OneTest for Longevity" launch and its market acceptance compared to established competitors.